Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …

Pirfenidone is an orally administered pyridine that has orphan designation for the treatment
of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Background Patients with idiopathic pulmonary fibrosis (IPF) demonstrate a range of lung
function impairment. However, the efficacy of antifibrotics compared with placebo has not …

Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

Pirfenidone (Esbriet®) is an orally administered, synthetic, pyridone compound that is
approved for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (IPF) …

Backgroud Previous pirfenidone trials have only involved patients with mild-to-moderate
idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the safety and …

Background: Pirfenidone is a novel antifibrotic drug for the treatment of mild-to-moderate
idiopathic pulmonary fibrosis (IPF). However, adverse events may offset treatment benefits …